Treatment for acute myeloid leukemia (AML) during its first complete remision with the monoclonal antibody Mylotarg ® (anti-CD33/calicheamicina) pre- and post- autologous transplant of hematopoietic stem cells
ESTADO CLÍNICO
En marcha
FASE/S DEL ENSAYO
Fase II
PATOLOGÍA
Leucemia mieloide aguda, Trasplante de progenitores hematopoyéticos, Linfoma, Leucemia
FECHA DE APERTURA
Mayo, 2006
FECHA DE CIERRE
,
CRITERIOS DE INCLUSIÓN
Acute myeloid leukemia (AML) during its first complete remision and with high relapse risk, pre- and post- autologous hematopoiteic transplant
CRITERIOS DE EXCLUSIÓN
No especificado
DESCRIPCIÓN
Leukemia relapse frequencies pre- and post- autologous trasplant of hematopoitec stem cells (historic control)
PALABRAS CLAVE
acute myeloid leukemia, aml, autologous, autologous transplant, de novo aml, flt3, hematopoietic, leukemia, mrd
